Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.81
PLX's Cash to Debt is ranked higher than
53% of the 1438 Companies
in the Global Biotechnology industry.

( Industry Median: 51.73 vs. PLX: 0.81 )
PLX' s 10-Year Cash to Debt Range
Min: 0.81   Max: No Debt
Current: 0.81

Equity to Asset -0.71
PLX's Equity to Asset is ranked lower than
52% of the 1086 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. PLX: -0.71 )
PLX' s 10-Year Equity to Asset Range
Min: -0.71   Max: 0.88
Current: -0.71

-0.71
0.88
F-Score: 3
Z-Score: -3.72
M-Score: -2.33
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -166.25
PLX's Operating margin (%) is ranked higher than
67% of the 1163 Companies
in the Global Biotechnology industry.

( Industry Median: -91.29 vs. PLX: -166.25 )
PLX' s 10-Year Operating margin (%) Range
Min: -8239.43   Max: -14.61
Current: -166.25

-8239.43
-14.61
Net-margin (%) -197.51
PLX's Net-margin (%) is ranked higher than
65% of the 1163 Companies
in the Global Biotechnology industry.

( Industry Median: -76.91 vs. PLX: -197.51 )
PLX' s 10-Year Net-margin (%) Range
Min: -8103.09   Max: -14.27
Current: -197.51

-8103.09
-14.27
ROA (%) -31.41
PLX's ROA (%) is ranked higher than
69% of the 1445 Companies
in the Global Biotechnology industry.

( Industry Median: -25.65 vs. PLX: -31.41 )
PLX' s 10-Year ROA (%) Range
Min: -372.46   Max: 1.59
Current: -31.41

-372.46
1.59
ROC (Joel Greenblatt) (%) -202.04
PLX's ROC (Joel Greenblatt) (%) is ranked higher than
75% of the 1405 Companies
in the Global Biotechnology industry.

( Industry Median: -346.25 vs. PLX: -202.04 )
PLX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -988.83   Max: -4.83
Current: -202.04

-988.83
-4.83
Revenue Growth (3Y)(%) 17.00
PLX's Revenue Growth (3Y)(%) is ranked higher than
86% of the 773 Companies
in the Global Biotechnology industry.

( Industry Median: 2.50 vs. PLX: 17.00 )
PLX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 236.2
Current: 17

0
236.2
EBITDA Growth (3Y)(%) -14.90
PLX's EBITDA Growth (3Y)(%) is ranked higher than
69% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. PLX: -14.90 )
PLX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -53.6   Max: 84.2
Current: -14.9

-53.6
84.2
EPS Growth (3Y)(%) -9.40
PLX's EPS Growth (3Y)(%) is ranked higher than
74% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. PLX: -9.40 )
PLX' s 10-Year EPS Growth (3Y)(%) Range
Min: -49.7   Max: 54.6
Current: -9.4

-49.7
54.6
» PLX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

PLX Guru Trades in Q2 2013

Jean-Marie Eveillard 500,000 sh (unchged)
Manning & Napier Advisors, Inc 159,710 sh (-88.85%)
» More
Q3 2013

PLX Guru Trades in Q3 2013

Jean-Marie Eveillard 500,000 sh (unchged)
Manning & Napier Advisors, Inc Sold Out
» More
Q4 2013

PLX Guru Trades in Q4 2013

Jean-Marie Eveillard 700,000 sh (+40.00%)
» More
Q1 2014

PLX Guru Trades in Q1 2014

Jean-Marie Eveillard Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with PLX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 12.25
PLX's P/S is ranked higher than
69% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 37.00 vs. PLX: 12.25 )
PLX' s 10-Year P/S Range
Min: 10.94   Max: 748
Current: 12.25

10.94
748
Current Ratio 2.50
PLX's Current Ratio is ranked higher than
62% of the 1401 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. PLX: 2.50 )
PLX' s 10-Year Current Ratio Range
Min: 1.74   Max: 91.65
Current: 2.5

1.74
91.65
Quick Ratio 2.25
PLX's Quick Ratio is ranked higher than
62% of the 1401 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. PLX: 2.25 )
PLX' s 10-Year Quick Ratio Range
Min: 1.72   Max: 91.65
Current: 2.25

1.72
91.65
Days Inventory 283.16
PLX's Days Inventory is ranked higher than
79% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. PLX: 283.16 )
PLX' s 10-Year Days Inventory Range
Min: 24.15   Max: 403.33
Current: 283.16

24.15
403.33
Days Sales Outstanding 45.36
PLX's Days Sales Outstanding is ranked higher than
88% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 139.31 vs. PLX: 45.36 )
PLX' s 10-Year Days Sales Outstanding Range
Min: 14.95   Max: 2016.91
Current: 45.36

14.95
2016.91

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.30
PLX's Price/Median PS Value is ranked higher than
98% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. PLX: 0.30 )
PLX' s 10-Year Price/Median PS Value Range
Min: 0.01   Max: 3.78
Current: 0.3

0.01
3.78
Earnings Yield (Greenblatt) -13.90
PLX's Earnings Yield (Greenblatt) is ranked higher than
50% of the 1393 Companies
in the Global Biotechnology industry.

( Industry Median: -5.90 vs. PLX: -13.90 )
PLX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -16.4   Max: 0
Current: -13.9

-16.4
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:PBD.Germany, PLX.Israel,
Protalix BioTherapeutics, Inc. was incorporated in Florida on April 1992. The Company and its wholly-owned subsidiary, Protalix Ltd. operate as biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company's proprietary ProCellEx protein expression system or ProCellEx. The Company's product development candidate is prGCD for the treatment of Gaucher disease, which the Company is developing using its ProCellEx protein expression system. Using its ProCellEx system, it is developing a pipeline of proprietary and biosimilar or 'generic' versions of recombinant therapeutic proteins based on its plant cell-based expression technology that target large, established pharmaceutical markets and that rely upon known biological mechanisms of action. The Company's initial commercial focus has been on complex therapeutic proteins, including proteins for the treatment of genetic disorders, such as Gaucher disease and Fabry disease. The biotechnology and pharmaceutical industries are characterized by rapidly evolving technology and significant competition. Competition from numerous existing companies and others entering the fields in which it operates is intense and expected to increase. As of December 31, 2013 the Company holds 49 patents. The testing, manufacture, distribution, advertising and marketing of drug products are subject to extensive regulation by federal, state and local governmental authorities in the United States, including the FDA, and by similar authorities in other countries.
» More Articles for PLX

Headlines

Articles On GuruFocus.com
Avago Technologies' Memory, FBAR, and Connectivity Business Will Take It Higher Oct 23 2014 
Weekly CFO Sells Highlight: AXP, CRAY, PLX, KMB, ITW, CATM, CAR May 07 2012 
Protalix BioTherapeutics Inc Reports Operating Results (10-K) Feb 23 2011 
Protalix BioTherapeutics Inc Reports Operating Results (10-Q) Nov 08 2010 
Protalix BioTherapeutics Inc (PLX) VP, CFO Yossi Maimon sells 70,000 Shares Oct 08 2010 
Protalix BioTherapeutics Inc (PLX) VP, CFO Yossi Maimon sells 70,000 Shares Sep 08 2010 
Protalix BioTherapeutics Inc Reports Operating Results (10-Q) Aug 05 2010 
Protalix BioTherapeutics Inc (PLX) CEO and President David Aviezer sells 244,238 Shares Oct 22 2009 
Protalix BioTherapeutics Inc (PLX) VP, CFO Yossi Maimon sells 150,000 Shares Oct 20 2009 
Protalix BioTherapeutics Inc Reports Operating Results (10-Q) Aug 03 2009 


More From Other Websites
Surging Earnings Estimates Signal Good News for Protalix BioTherapeutics (PLX) - Tale of the Tape Apr 10 2015
Protalix BioTherapeutics (PLX) Shares March Higher, Can It Continue? - Tale of the Tape Apr 09 2015
Why Protalix BioTherapeutics (PLX) Stock Might be a Great Pick - Tale of the Tape Apr 02 2015
Protalix BioTherapeutics (PLX): An Off-the-Radar Potential Winner - Tale of the Tape Mar 20 2015
PROTALIX BIOTHERAPEUTICS, INC. Financials Mar 19 2015
Protalix BioTherapeutics Reports Full Year 2014 Financial Results and Provides Corporate Update Mar 12 2015
Protalix reports 4Q loss Mar 12 2015
Protalix reports 4Q loss Mar 12 2015
PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition Mar 12 2015
Protalix BioTherapeutics Reports Full Year 2014 Financial Results and Provides Corporate Update Mar 12 2015
PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events Feb 12 2015
Protalix BioTherapeutics Presents Additional Positive Phase I/II Interim Clinical Data on PRX-102... Feb 12 2015
Protalix Finishes Patient Enrollment for Fabry Disease Study - Analyst Blog Feb 04 2015
PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events Feb 02 2015
Protalix BioTherapeutics Completes Enrollment in Phase I/II Clinical Trial of PRX-102 for Fabry... Feb 02 2015
Pharmaceuticals, Therapeutics And A Retailer On The Move Thursday Morning Jan 08 2015
Protalix BioTherapeutics Reports Positive Interim Data From Phase I/II Clinical Trial of PRX-102 for... Jan 08 2015
PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events Jan 08 2015
Protalix BioTherapeutics to Present at the 2015 J.P. Morgan Healthcare Conference Jan 05 2015
Protalix BioTherapeutics Announces New Strategy for Accelerated Growth Jan 05 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK